Skip to main content
Premium Trial:

Request an Annual Quote

Mediomics Lands $460K STTR Grant

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mediomics has reeled in $460,000 from the National Institute of General Medical Sciences through a Phase II Small Business Technology Transfer (STTR) grant.

The company plans to use the funds to develop and increase the sensitivity of its biosensor technology and to develop its PINCER protein assay. Mediomics is commercializing core technologies it has licensed under an exclusive agreement with Saint Louis University.

Mediomics' technologies include a DNA-binding protein-based bioassay and biochip platform; the related molecular PINCER-based biosensor, bioassay, and biochip platforms; and methods for screening and developing new high affinity capture reagents for research, diagnostic, and therapeutic applications.

The St. Louis-based company is focused on developing assay kits, biosensors, and microarrays for academic and corporate research, point-of-care testing, process control, and the medical and environmental research markets. These assays will be used to quantify important macromolecules, including ligands, proteins, protein complexes, and pathogens.

The company said it also plans to develop high-throughput screening kits for drug discovery targets and to support expansion into clinical diagnostic markets.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.